Real World Glycemic Effectiveness of Linagliptin

Completed

• Conditions: Diabetes Mellitus, Type 2
• Interventions: Drug: Linagliptin

• Registration Number: NCT03338803
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

A non-interventional cohort study using existing data from patients in the Optum Clinical Database which contains electronic health record (EHR) data from providers across the United States to determine whether there is comparable effectiveness of linagliptin on glycemic effectiveness

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-11-08
• Study First Submitted QC: 2017-11-08
• Study First Posted: 2017-11-09
• Study Start: 2017-11-21
• Primary Completion: 2018-02-02
• Study Completion: 2018-02-02
• Status Verified: 2019-02
• Results First Submitted: 2019-02-01
• Results First Submitted QC: 2019-02-01
• Last Update Submitted: 2019-02-01
• Results First Posted: 2019-05-06
• Last Update Posted: 2019-05-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 11001

Inclusion Criteria

• ≥ 1 written prescription for linagliptin (Tradjenta®, Jentadueto®, or Jentadueto XR®)in the EHR (electronic health record) data during the identification period
• ≥ 40 years of age based on the year of the index date
• First active date in the EHR is ≥ 180 days prior to the index date
• ≥ 1 diagnosis code representing Type 2 diabetes (T2DM) in the EHR data during the 180-day pre-index period or on the index date
• ≥ 1 HbA1c value during the 180-day pre-index period or on the index date
• ≥ 1 HbA1c value 60 to 180 days after the index date

Read More

Exclusion Criteria

• ≥ 1 written prescription, medication administration or medication history record for linagliptin or other dipeptidyl peptidase (DPP-4) inhibitor in the EHR data during the 180-day pre-index period
• ≥ 1 written prescription or medication administration for a new antihyperglycemic medication other than linagliptin on the index date New antihyperglycemic medication will be defined as a written prescription or medication administration for any antihyperglycemic medication that was not present in the patient's written prescription, medication administration, or medication history records during the 180-day pre-index period.

Individual antihyperglycemic medications will be distinguished by generic name using the column labelled "Medication Name" in Tables 2 through 13. Combination products containing two generic ingredients will be considered as two distinct antihyperglycemic medications Note: This exclusion criterion is designed to exclude patients from the study sample if they start a new antihyperglycemic medication other than linagliptin on the index date. Patients that start a new antihyperglycemic medication in the follow-up period will not be removed from the study sample to avoid creating a biased sample. Addition of a new antihyperglycemic medication during follow-up will be evaluated through the sensitivity analysis described in Section 9.7.4.4. While we will be capturing additions of new therapies, discontinuation of linagliptin is not able to be accurately measured in electronic record data. The electronic record data capture prescriptions written by a prescriber, but it is not possible to know if patients received and adhered to their medication and there are no structured data fields to identify if and when a medication was discontinued by the patient or the provider

• ≥ 1 diagnosis code or procedure code representing renal transplant, solid organ transplant, or bone marrow transplant in the EHR data during the 180-day pre-index period or on the index date
• ≥ 1 diagnosis code representing malignancy in the EHR data during the 180-day preindex period or on the index date

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with a written prescription for linagliptin	Linagliptin	-

Primary Outcome Measures

Name	Time	Method
Change in Glycosylated Hemoglobin (HbA1c) Across Age Categories	Baseline and 60 to 180 days	Change in HbA1c among adults with type 2 diabetes mellitus (T2DM) within the 60 to 180 days following initiation of linagliptin across pre-defined age categories (40 to 54 years, 40 to 54 years, 65 to 74 years and 75+ years).; Change in HbA1c, was calculated for each patient by subtracting the patient's last (most recent) HbA1c value during the pre-index period (including the index date) from the patient's last (most recent) HbA1c value 60 to 180 days after the index date.
Change in Glycosylated Hemoglobin (HbA1c) Across Renal Function Categories	Baseline and 60 to 180 days	Change in HbA1c among adults with type 2 diabetes mellitus (T2DM) within the 60 to 180 days following initiation of linagliptin across pre-defined renal function categories.; Change in HbA1c, was calculated for each patient by subtracting the patient's last (most recent) HbA1c value during the pre-index period (including the index date) from the patient's last (most recent) HbA1c value 60 to 180 days after the index date. Renal function categories were presented based on patients with a pre-index estimated glomerular filtration rate (eGFR) value (eGFR\<30, eGFR 30 to 44, eGFR 45 to 59, eGFR 60 to 89, eGFR ≥ 90 milliliter/ minute/1.73 meter\^2 and eGFR not available).

Secondary Outcome Measures

Name	Time	Method
Percentage of Adults With T2DM Who Achieve HbA1c < 7.0% Across Renal Function Categories	60 to 180 days	Percentage of adults with T2DM who achieve HbA1c \< 7.0% within the 60 to 180 days following initiation of linagliptin across pre-defined renal function categories. Renal function categories were presented based on patients with a pre-index estimated glomerular filtration rate (eGFR) value (eGFR\<30, eGFR 30 to 44, eGFR 45 to 59, eGFR 60 to 89, eGFR ≥ 90 milliliter/ minute /1.73 meter\^2 and eGFR not available).
Percentage of Adults With T2DM Who Achieve HbA1c < 7.0% Across the Pre-defined Age Categories	60 to 180 days	Percentage of adults with T2DM who achieve HbA1c \< 7.0% within the 60 to 180 days following initiation of linagliptin across pre-defined age categories (40 to 54 years, 40 to 54 years, 65 to 74 years and 75+ years).

Trial Locations

Locations (1)

Optum; 🇺🇸 Eden Prairie, Minnesota, United States